A semi-mechanistic model for the effects of a novel glucagon receptor antagonist on glucagon and the interaction between glucose, glucagon, and insulin applied to adaptive phase ii design

AAPS Journal

Volumn 16, Issue 6, 2014, Pages 1259-1270

  Peng, Joanna Z ^a,b   Denney, William S ^a   Musser, Bret J ^a   Liu, Rong ^a   Tsai, Kuenhi ^a   Fang, Lanyan ^a   Reitman, Marc L ^a   Troyer, Matthew D ^a   Engel, Samuel S ^a   Xu, Lei ^a   Stoch, Aubrey ^a   Stone, Julie A ^a   Kowalski, Ken G ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b AMGEN INC   (United States)

^c ANN ARBOR PHARMACOMETRICS GROUP   (United States)

Author keywords

Glucagon challenge; Glucagon receptor antagonist; Glucose and insulin; Modeling and simulation; Type 2 diabetes

Indexed keywords

GLUCAGON; GLUCAGON RECEPTOR ANTAGONIST; GLUCOSE; HORMONE ANTAGONIST; INSULIN; METFORMIN; MK 3577; OCTREOTIDE; PLACEBO; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLUCAGON RECEPTOR; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER PROGRAM; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; IC50; MALE; MATHEMATICAL MODEL; MORNING DOSAGE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PREDICTION; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL MODEL; STEADY STATE; ANALYSIS; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG INTERACTION; METABOLISM; MIDDLE AGED;

ADULT; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; GLUCAGON; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RECEPTORS, GLUCAGON;

EID: 84919635582     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9648-x     Document Type: Article

References (23)

1. Porte Jr D. Beta-cells in type II diabetes mellitus. Diabetes. 1991;40:166–80.
2. Aronoff SL, Berkowitz K, Shreiner B, Want L. Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectr. 2004;17:183–90.
3. Rizza RA, Cryer PE, Haymond MW, Gerich JE. Adrenergic mechanisms for the effects of epinephrine on glucose production and clearance in man. J Clin Invest. 1980;65:682–9.
4. Cheng D. Prevalence, predisposition and prevention of type II diabetes. Nutr Metab. 2005;2:29.
5. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.
6. Li XC, Zhuo JL. Targeting glucagon receptor signaling in treating metabolic syndrome and renal injury in type 2 diabetes: theory versus promise. Clin Sci (Lond). 2007;113(4):183–93.
7. Hare KJ. Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus. Dan Med Bull. 2010;57:B4181.
8. Del Guercio MJ, di Natale B, Gargantini L, Garlaschi C, Chiumello G. Effect of somatostatin on blood sugar, plasma growth hormone, and glucagon levels in diabetic children. Diabetes. 1976;25:550–3.
9. Silber HE, Jauslin PM, Frey N, Gieschke R, Simonsson USH, Karlsson MO. An integrated model for glucose and insulin regulation in healthy volunteers and type 2 diabetic patients following intravenous glucose provocations. J Clin Pharmacol. 2007;47:1159–71.
10. Jauslin PM, Silber HE, Frey N, Gieschke R, Simonsson USH, Jorga K, et al. An integrated glucose-insulin model to describe oral glucose tolerance test data in type 2 diabetics. J Clin Pharmacol. 2007;47:1244–55.
11. Man CD, Rizza RA, Cobelli C. Meal simulation model of the glucose-insulin system. IEEE Trans Biomed Eng. 2007;54:1740–9.
12. de Winter W, DeJongh J, Post T, Ploeger B, Urquhart R, Moules I, et al. A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying type 2 diabetes mellitus. J Pharmacokinet Pharmacodyn. 2006;33:313–43.
13. Hovorka R, Canonico V, Chassin LJ, Haueter U, Massi-Benedetti M, Federici MO, et al. Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiol Meas. 2004;25:905–20.
14. Lau YY, Ma P, Gibiansky L, Komorowski R, Wang J, Wang G, et al. Pharmacokinetic and pharmacodynamic modeling of a monoclonal antibody antagonist of glucagon receptor in male ob/ob mice. AAPS J. 2009;11:700–9.
15. Schneck KB, Zhang X, Bauer R, Karlsson MO, Sinha VP. Assessment of glycemic response to an oral glucokinase activator in a proof of concept study: application of a semi-mechanistic, integrated glucose-insulin-glucagon model. J Pharmacokinet Pharmacodyn. 2013;40:67–80.
16. Sorensen JT. A physiologic model of glucose metabolism in man and its use to design and assess improved insulin therapies for diabetes. Thesis (Sc. D.), Massachusetts Institute of Technology, Dept. of Chemical Engineering; 1985. http://dspace.mit.edu/handle/1721.1/15234.
17. Schaller S, Willmann S, Lippert J, Schaupp L, Pieber TR, Schuppert A, et al. A generic integrated physiologically based whole-body model of the glucose-insulin-glucagon regulatory system. CPT Pharmacometrics Syst Pharmacol. 2013;2:e65.
18. Harris AG. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut. 1994;35:S1–4. doi:10.1136/gut.35.3_Suppl.S1.
19. Chanson P, Timsit J, Harris AG. Clinical pharmacokinetics of octreotide: therapeutic applications in patients with pituitary tumors. Clin Pharmacokinet. 1993;25:375–91.
20. Holford N, Ma SC, Ploeger BA. Clinical trial simulation: a review. Nature. 2010;88:166–82.
21. Sloop KW, Cao JX, Siesky AM, Zhang HY, Bodenmiller DM, Cox AL, et al. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest. 2004;113:1571–81.
22. Engel SS, Reitman ML, Xu L, Andryuk PJ, Davies MJ, Kaufman KD, et al. Glycemic and lipid effects of the short-acting glucagon receptor antagonist MK-3577 in patients with type 2 diabetes. Presentation #1037-P, ADA 72nd Scientific Sessions. 2012.
23. Rohlfing CL, England JD, Tennill A, Little RR, Goldstein DE. Defining the relationship between plasma glucose and HbA1c. Diabetes Care. 2002;25(2):275–8.